Home Analyst Ratings SVB Leerink reiterates Sarepta Therapeutics rating to Outperform and sets new...

SVB Leerink reiterates Sarepta Therapeutics [SRPT] rating to Outperform and sets new price target at $125

SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research note dated 2021-01-08. That figure represents around a -26.01% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with UBS’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late October. Meanwhile, Raymond James had launched its coverage on SRPT with “an Outperform”, in a research note produced for clients August 25, 2020. In addition, there was a downgrade from Credit Suisse on August 20, 2020. The rater changed SRPT from “an Outperform” to “a Neutral”.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Sarepta Therapeutics Inc. [NASDAQ:SRPT] a Good Buy Right Now?

It should be noted that SRPT technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 88% Buy in the last week and compares with 40% Buy in the past month. Data from Sarepta Therapeutics Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 1.05 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.89 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.78 million shares.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

SRPT Price Performance

On Wall Street, Sarepta Therapeutics Inc. [NASDAQ:SRPT] finished Thursday’s session up 1.50% at $168.95. The stock went up to $174.30 at the same session while its lowest single day price was $166.93. In the last five days, it saw a fall of about -1.51%, Sarepta Therapeutics Inc. shares dropped by almost -0.90% since the beginning of the year. However, the share price has dropped to as low as -7.08% below its one year high. On 01/04/21, the company shares recorded $174.49, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $161.12. The company’s shares have inclined by 29.93% in the past year. The 50-day SMA achieved is $152.17 while the 200-day SMA is $144.66. Volume gained to 4.75 million from 0.91 million in the previous session.

SRPT Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 165.82 level, and in case of violation of this particular level, it will cause more drop to 162.69 level. On the upper level, 177.43 is still the key resistance. The stock may increase to the subsequent resistance at 173.19. The Relative Strength Index (RSI) pinned on the 14-day chart is 57.54, implying a neutral technical stance while the MACD stands at -5.47, meaning price will decrease in the next trading period. Percent R indicator moved to 62.19%, implying low price movement. Stochastic %K at 24.93% suggest selling the stock.

What is the short interest in Sarepta Therapeutics Inc.?

Short interest in the Sarepta Therapeutics Inc. stock has surged, increasing by 0.36 million shares to total 7.91 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.27 million, data from Yahoo Finance shows. The decrease of -4.55% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 11.85% of the overall float for the stock.

Sarepta Therapeutics Inc.’s Biggest Shareholders: Who Owns Sarepta Therapeutics Inc. [SRPT]?

Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 6,907,344 shares or roughly 8.75% of the outstanding SRPT shares. This means their shares have reduced by -61,716 from the 6,907,344 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Capital Research & Management Co updated stake is worth $945,357,099. Details in the latest 13F filings reveal that Fidelity Management & Research Co disposed off their -20.24% stake valued at $777,841,034 while BlackRock Fund Advisors cut theirs at $569,298,227. During the last quarter, Fidelity Management & Research Co liquidated -1,401,047 of its shares in Sarepta Therapeutics Inc. while BlackRock Fund Advisors sold -116,308 shares. The Janus Capital Management LLC’s holdings currently number 3,950,552 shares at $667445760.4. According to the firm’s last 13F report, Jennison Associates LLC shares in the company at filing stood at 2,605,072 shares, roughly $366,950,442.

SRPT Earnings Forecast For The Current Quarter

Sarepta Therapeutics Inc. [SRPT] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $148.68M and an earnings per share of -$1.8 for Dec 2020. Looking further ahead, the company is expected to report revenue of $157.85M at an EPS of -$1.53 for Mar 2021. The estimates represent upside of 42.80% and 24.00% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

SRPT Earnings Estimates For The Current Year

For the financial year, Sarepta Therapeutics Inc. [NASDAQ:SRPT] is expected to bring in revenue of $541.72M. The returns are nearly $160.89 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -6.7, higher than that of FY19 by $3.01. Estimates put this year’s earnings growth at 31.00%, 24.90% for the next, and at an annual 96.00% over the next 5-year period. As for sales, forecasts are for an increase of 42.20% in the current fiscal year and a further 42.80% over the following year.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Torchlight Energy Resources Inc. (TRCH) stock surged during current market trading. Here’s to know why?

Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock gained by 41.33% in the current market trading session. Torchlight Energy Resources is a vast growing oil...

The9 Ltd. (NCTY) stock declined during pre-market trading. Here’s the update

The9 Ltd. (NASDAQ: NCTY) stock plunged by 12% at the last close while the NCTY stock price fell by 7.03% during pre-market trading. The9...

The Dixie Group Inc. (DXYN) stock surged during pre-market trading given no recent news

The Dixie Group Inc. (NASDAQ: DXYN) stock gained by 11.55% in the pre-market trading session. However, there is no update available regarding this hike...

Why BancorpSouth Bank (BXS) stock plummeted on Friday?

BancorpSouth Bank (BXS) shares plummeted 9.39% in after-hours on Friday, June 18, 2021, and close the weekly business at $25.00 per share. Earlier, BXS's...

CureVac Inc. (CVAC) stock soar during pre-market trading. Here’s what you should know?

CureVac Inc. (NASDAQ: CVAC) stock declined by 38.99% at the last close while the CVAC stock price gains by 11.34% in the pre-market trading...

Anavex Inc. (AVXL) stock soars during pre-market trading. Let’s see why?

Anavex Inc. (AVXL) stock gained by 4.29% at the last close while the AVXL stock price surged by 12.38% in the pre-market trading session....

The9 Ltd. (NCTY) stock declined during pre-market trading. Here’s the update

The9 Ltd. (NASDAQ: NCTY) stock plunged by 12% at the last close while the NCTY stock price fell by 7.03% during pre-market trading. The9...

The Dixie Group Inc. (DXYN) stock surged during pre-market trading given no recent news

The Dixie Group Inc. (NASDAQ: DXYN) stock gained by 11.55% in the pre-market trading session. However, there is no update available regarding this hike...

Related News

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%....

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam